论文部分内容阅读
目的:了解P-选择素及其配体sLeA、sLeX在食管癌组织及区域淋巴结中的表达,探讨其与食管癌侵袭转移的关系。方法:应用组织芯片技术结合免疫组化检测食管鳞癌86例及其淋巴结P-选择素和sialy lewis A(sLeA)、sialylewis X(sLe X)的表达情况,并与16例正常食管鳞状上皮对照。结果:P-选择素在食管癌组织、正常食管鳞状上皮表达率分别为59.3%、12.5%(P<0.05),在转移淋巴结、非转移淋巴结中表达率分别为92.9%、31.3%(P<0.05)。sLeA在食管癌组织,正常食管组织中表达率分别为77.9%、6.25%(P<0.05),在转移淋巴结和非转移淋巴结中表达率分别为97.6%、20.3%(P<0.05)。sLe X食管癌组织、正常食管组织中表达率分别为15.1%、6.25%(P>0.05)。P-选择素和配体sLeA过度表达与食管鳞癌病理分级,TNM分期及淋巴结转移成显著相关性;而配体sLeX在食管癌组织中无过度表达。结论:P-选择素和配体sLeA在食管鳞癌组织、转移淋巴结中表达率明显升高,其与食管癌的侵袭转移有一定关系;配体sLeX与食管癌侵袭转移无关。
Objective: To investigate the expression of P-selectin and its ligands sLeA and sLeX in esophageal cancer tissues and regional lymph nodes and to explore their relationship with the invasion and metastasis of esophageal cancer. Methods: Tissue microarray was used to detect the expression of s-lysine A (sLeA) and sialyl-X (sLe X) in esophageal squamous cell carcinoma and 86 cases of esophageal squamous cell carcinoma Control. Results: The expressions of P-selectin in esophageal squamous cell carcinoma and normal esophageal squamous epithelium were 59.3% and 12.5%, respectively (P <0.05). The positive rates of P-selectin in metastatic lymph nodes and non-metastatic lymph nodes were 92.9% and 31.3% <0.05). The expression rates of sLeA in esophageal cancer tissues and normal esophageal tissues were 77.9% and 6.25%, respectively (P <0.05). The positive rates of sLeA in metastatic lymph nodes and non-metastatic lymph nodes were 97.6% and 20.3% (P <0.05). The expression rates of sLe X in esophageal cancer tissues and normal esophageal tissues were 15.1% and 6.25%, respectively (P> 0.05). Overexpression of s-selectin and ligand sLeA was significantly associated with pathological grade, TNM stage and lymph node metastasis of esophageal squamous cell carcinoma, while sLeX ligand was not over-expressed in esophageal cancer tissues. CONCLUSIONS: The expression of P-selectin and ligand sLeA in esophageal squamous cell carcinoma and metastatic lymph nodes is significantly increased, which is related to the invasion and metastasis of esophageal cancer. The ligand sLeX has nothing to do with the invasion and metastasis of esophageal cancer.